Influvac

Influenza virus vaccine, the active ingredient in Influvac, is a vaccine presented as a sterile suspension for intramuscular and subcutaneous use. It is designed to prevent influenza infection caused by influenza A and B viruses in individuals aged six months and older.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. All shipments are managed under controlled temperature conditions to preserve vaccine potency.

Influvac is indicated for the prevention of influenza caused by circulating influenza A and B viruses.

Seasonal influenza: reduces the risk of laboratory‑confirmed influenza infection in the general population. High‑risk groups (e.g., elderly, chronic disease patients): lowers the likelihood of severe disease and related complications. Healthcare workers: helps prevent transmission of influenza in clinical settings.

Influvac may be associated with local and systemic reactions following administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise. - Headache or muscle aches: mild systemic symptoms.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder reported after influenza vaccination.

Before administering Influvac, consider the following precautions to ensure safe use.

- Contraindication: do not vaccinate individuals with a known severe allergy to any vaccine component. - History of Guillain‑Barré syndrome: assess risk and discuss with a healthcare professional. - Acute febrile illness: postpone vaccination until recovery. - Pregnancy: evaluate benefits versus risks with a qualified provider. - Immunocompromised patients: vaccine may be less immunogenic; monitor response. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Influvac has limited drug interaction potential, but certain co‑administered agents warrant attention.

Major Interactions (Avoid): - Live attenuated vaccines: avoid simultaneous administration; separate by at least 4 weeks. - Immunoglobulin therapy: may reduce vaccine efficacy if given within 2 weeks before or after vaccination.

Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen, ibuprofen): may mask fever, but generally safe. - Antiviral medications (e.g., oseltamivir): no direct interaction, but timing may affect immune response. - Immunosuppressive drugs: may diminish antibody response; monitor serologic protection.